Anaptysbio, Inc · Brief

Next report

3 days

Nov 5 · after closeest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

2 of 8≥ implied

Nov 5 '24±10.5%▲+11.72%×1.12

Feb 27 '25±18.0%▲+2.56%×0.14

May 5 '25±18.4%▼−2.94%×0.16

Aug 6 '25±12.0%▼−9.63%×0.80

Q3 FY25±16.7%▲+3.63%×0.22

Q4 FY25±10.0%▲+9.76%×0.97

Q1 FY26±14.1%▲+14.61%×1.03

May 12 '26±6.7%▼−4.41%×0.66

quarterimplied−20%0+20%realized×

May '26±6.7%▼−4.41%×0.66

Q1 FY26±14.1%▲+14.61%×1.03

Q4 FY25±10.0%▲+9.76%×0.97

Q3 FY25±16.7%▲+3.63%×0.22

Aug '25±12.0%▼−9.63%×0.80

May '25±18.4%▼−2.94%×0.16

2 older reports

Feb '25±18.0%▲+2.56%×0.14

Nov '24±10.5%▲+11.72%×1.12

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 5 report · est.

Bull2 of 4

4disclosed supplier and customer ties reported in SEC filingsSEC filings

4tracked funds holding ANABN-PORT · Aug 31 '26

Bear2 of 4

6 of 8recent reports with moves realized below the options implied rangeEarnings history

6 of 25largest reporting managers trimming their stake in the latest quarter13F · Jun 30 '26

AI captions · Sep 16 '26once per report · top 2 per case

ANAB report session

No linked exposure.

Oct 22impliedImplied move: ±17.7% into Nov 5 earnings (Oct 22 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.